Erenumab
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Erenumab?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Erenumab, sold under the brand name Aimovig, is a medication which blocks the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.[3][4][5] It is administered by subcutaneous injection.[3][4]
Quick Facts Monoclonal antibody, Type ...
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CGRPR |
Clinical data | |
Trade names | Aimovig |
Other names | AMG-334, erenumab-aooe |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618029 |
License data | |
Pregnancy category |
|
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 82% (estimated) |
Metabolism | Proteolysis |
Elimination half-life | 28 days |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6472H9964N1728O2018S50 |
Molar mass | 145871.98 g·mol−1 |
Close
Erenumab, which was developed by Amgen and Novartis,[5] was approved in May 2018, and was the first CGRPR antagonist to be approved by the U.S. Food and Drug Administration.[6] In 2020, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]